Bayer Completes Acquisition of KaNDy Therapeutics to Expand Women's Health Pipeline

Yiou Health, September 9 News:BayerAnnounced Today the Completion of the Acquisition of the UK Biotechnology CompanyKaNDy Therapeuticsthe acquisition of KaNDy Therapeutics Ltd. This acquisition aims to expand the drug development pipeline in the field of women's health.

Under the terms of the agreement, Bayer will pay an upfront consideration of $425 million, with potential milestone payments of up to $450 million prior to launch, followed by possible three-digit sales milestone payments thereafter.

KaNDy Therapeutics is a clinical-stage biotechnology company founded in 2017 and is a subsidiary of NeRRe Therapeutics Ltd. It is reported that KaNDy Therapeutics has recently completed the Phase IIb clinical study of NT-814, announcing its treatmentMenopausePositive data on common symptoms, such as hot flashes and night sweats (vasomotor symptoms). The Phase III clinical trial of this drug is expected to begin in 2021. Once approved, the peak global sales potential for NT-814 could exceed €1 billion.

NT-814 is aNon-hormonalNeurokinin-1,3 Receptor Antagonists for Once-Daily Oral AdministrationAntagonist, has been studied for the treatment of menopausal symptoms and opioid use disorder. It was originally developed by GlaxoSmithKline, spun off to NeRRe Therapeutics in 2012, and subsequently spun off to KaNDy Therapeutics in 2017.

Studies have shown that up to 75% of menopausal women experience vasomotor symptoms associated with menopause. Dr. Sebastian Guth, President of Bayer’s Pharmaceuticals Division in the Americas, stated, “This acquisition underscores our commitment to women’s health. It not only expands our portfolio but also, pending approval, has the potential to provide a new therapeutic option that could significantly impact women’s lives.”

Women’s health, including menopause management, has always been at the core of Bayer’s gynecology business.

In early 2020, Bayer announced an expansion of its collaboration with Evotec, launching a new five-year, multi-target partnership to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), the most common gynecological endocrine disorder in women. Meanwhile, Bayer entered into an exclusive licensing agreement with Daré Bioscience for the U.S. market, focusing on a non-hormonal, once-monthly vaginal contraceptive currently in clinical development.

This article is sourced from EqualOcean, an original piece by author Gao Yushan. For reprints or collaborations, please click here.Reprint Notice, Unauthorized reproduction will be subject to legal action.